<unk>  is structurally similar to serotonin (5-HT), and is a 5-HT receptor (types 5-HT1D and 5-HT1B) agonist.<unk> 's primary therapeutic effect, however, is in its inhibition of the release of Calcitonin gene-related peptide (CGRP), likely through its 5-HT1D/1B receptor-agonist action. This is substantiated by the efficacy of newly developed CGRP antagonists and antibodies in the preventative treatment of migraine. However, how agonism of the 5-HT1D/1B receptors inhibits CGRP release is not fully understood. CGRP is believed to cause sensitization of trigeminal nociceptive neurons, contributing to the pain experienced in migraine.<unk>  is also shown to decrease the activity of the trigeminal nerve, which presumably accounts for<unk> 's efficacy in treating cluster headaches. The injectable form of the drug has been shown to abort a cluster headache within 30 minutes in 77% of cases.
Sumatriptan
Eletriptan
Frovatriptan
Rizatriptan
Almotriptan
Naratriptan
Triptan
Zolmitriptan